Compare LEDS & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | HOWL |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 18.9M |
| IPO Year | 2010 | 2021 |
| Metric | LEDS | HOWL |
|---|---|---|
| Price | $1.90 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 31.0K | ★ 642.1K |
| Earning Date | 04-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.12 | 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,009,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 729.81 | N/A |
| 52 Week Low | $1.01 | $0.34 |
| 52 Week High | $3.37 | $2.23 |
| Indicator | LEDS | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 33.27 |
| Support Level | $1.59 | $0.36 |
| Resistance Level | $2.02 | $0.74 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 42.11 | 17.04 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.